Arlington Partners’s Novo Nordisk NVO Stock Holding History

Arlington Partners’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$325K	Buy	6,777 +283	+4%	+$12.2K	0.59%	5
2026 Q1	$239K	Buy	+6,494	New	+$308K	0.48%	37
2025 Q4	–	Sell	-93,006	Closed	-$5.16M	–	37
2025 Q3	$5.16M	Buy	93,006 +26,928	+41%	+$1.58M	1.78%	15
2025 Q2	$4.56M	Buy	66,078 +16,733	+34%	+$1.14M	1.68%	19
2025 Q1	$3.43M	Buy	49,345 +19,933	+68%	+$1.65M	1.34%	54
2024 Q4	$2.53M	Hold	29,412	–	–	0.98%	50
2024 Q3	$3.5M	Buy	29,412 +5,935	+25%	+$792K	1.37%	56
2024 Q2	$3.35M	Sell	23,477 -3,680	-14%	-$488K	1.66%	12
2024 Q1	$3.49M	Sell	27,157 -3,018	-10%	-$359K	1.78%	12
2023 Q4	$3.12M	Sell	30,175 -1,177	-4%	-$116K	0.9%	32
2023 Q3	$2.85M	Buy	31,352 +3,930	+14%	+$346K	1.17%	26
2023 Q2	$2.22M	Hold	27,422	–	–	0.34%	30
2023 Q1	$2.18M	Sell	27,422 -12,550	-31%	-$890K	0.31%	28
2022 Q4	$2.7M	Hold	39,972	–	–	0.43%	24
2022 Q3	$1.99M	Buy	39,972 +646	+2%	+$34.6K	0.8%	28
2022 Q2	$2.19M	Sell	39,326 -9,984	-20%	-$554K	0.73%	27
2022 Q1	$2.74M	Sell	49,310 -7,352	-13%	-$377K	0.77%	27
2021 Q4	$3.17M	Sell	56,662 -7,914	-12%	-$429K	0.85%	23
2021 Q3	$3.1M	Sell	64,576 -21,288	-25%	-$1.03M	0.89%	25
2021 Q2	$3.6M	Buy	85,864 +2,006	+2%	+$77.8K	1.25%	17
2021 Q1	$2.83M	Buy	83,858 +12,970	+18%	+$462K	1.03%	18
2020 Q4	$2.48M	Buy	70,888 +836	+1%	+$28.9K	1.14%	18
2020 Q3	$2.43M	Hold	70,052	–	–	1.33%	16
2020 Q2	$2.29M	Sell	70,052 -7,050	-9%	-$225K	1.29%	19
2020 Q1	$2.32M	Buy	77,102 +61,732	+402%	+$1.84M	1.21%	18
2019 Q4	$445K	Buy	15,370 +3,440	+29%	+$95.3K	0.27%	30
2019 Q3	$308K	Sell	11,930 -84,370	-88%	-$2.13M	0.2%	38
2019 Q2	$2.46M	Buy	96,300 +86,380	+871%	+$2.13M	1.1%	21
2019 Q1	$259K	Sell	9,920 -45,980	-82%	-$1.13M	0.19%	50
2018 Q4	$1.29M	Buy	55,900 +1,380	+3%	+$30.7K	0.84%	22
2018 Q3	$1.28M	Buy	54,520 +760	+1%	+$18.5K	0.9%	25
2018 Q2	$1.24M	Hold	53,760	–	–	1.17%	19
2018 Q1	$1.32M	Buy	53,760 +3,850	+8%	+$101K	1.25%	19
2017 Q4	$1.34M	Buy	+49,910	New	+$1.27M	1.38%	19

Other funds holding NVO

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

AIP

ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

ONB

Old National Bancorp Evansville, Indiana $5.02B AUM 25.65% 1-Year Est. Return

VFM

Viking Fund Management Minot, North Dakota $1.12B AUM 44.65% 1-Year Est. Return

QCM

QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return

ERP

Eldred Rock Partners San Antonio, Texas $465M AUM 48.86% 1-Year Est. Return

BIAS

Beacon Investment Advisory Services Morristown, New Jersey $2.69B AUM 35.07% 1-Year Est. Return

Arlington Partners's NVO Position: Q2 2026 in Review

Arlington Partners increased its Novo Nordisk (NVO) stake by 4.4% in Q2 2026, buying an estimated $12.2K and bringing the position to 6,777 shares worth $325K. The position accounts for 0.59% of the portfolio, ranked #5.

Arlington Partners first reported a position in NVO in Q4 2017 and has held it in 34 quarters since. The position peaked at $5.16M in Q3 2025. 205 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Arlington Partners held 6,777 shares of Novo Nordisk worth $325K as of Q2 2026.
Arlington Partners bought 283 Novo Nordisk shares in Q2 2026, an estimated $12.2K.
Novo Nordisk made up 0.59% of Arlington Partners's portfolio in Q2 2026, its #5 holding.
Arlington Partners first reported a position in Novo Nordisk in Q4 2017 and has held it in 34 quarters since.
Arlington Partners's Novo Nordisk position peaked at $5.16M in Q3 2025.
205 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Arlington Partners's 13F filing for Q2 2026, filed 7 Jul 2026.